TERSERA THERAPEUTICS LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://tersera.com
Phase 2 Study IV QUZYTTIRâ„¢ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Phase 2
Completed
- Conditions
- Oncology Patients Receiving Chemotherapy
- Interventions
- Drug: Diphenhydramine 50 mg/mLDrug: Cetirizine HCl 10 mg/mLDrug: anti-CD20 such as Rituximab or Paclitaxel
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- TerSera Therapeutics LLC
- Target Recruit Count
- 34
- Registration Number
- NCT04189588
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸St.Joseph Heritage Care, Napa, California, United States
🇺🇸Eisenhower Medical Center, Rancho Mirage, California, United States
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- TerSera Therapeutics LLC
- Target Recruit Count
- 53
- Registration Number
- NCT03790111
- Locations
- 🇺🇸
TerSera Investigational Site, San Antonio, Texas, United States
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- TerSera Therapeutics LLC
- Target Recruit Count
- 223
- Registration Number
- NCT03223428
- Locations
- 🇺🇸
RTI-HS, Research Triangle Park, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath